Maravai Lifesciences Holdings (MRVI) Capital Leases (2020 - 2026)

Maravai Lifesciences Holdings' Capital Leases history runs 6 years deep, the most recent figure standing at $29.9 million for Q1 2026.

• On a quarterly basis, Capital Leases fell 3.28% year-over-year to $29.9 million in Q1 2026; TTM through Mar 2026 was $29.9 million, a 3.28% decrease from a year earlier, with the FY2025 full-year figure at $30.1 million, down 3.1% from the prior year.
• Capital Leases retreated to $29.9 million in Q1 2026 per MRVI's latest filing, from $30.1 million in the prior quarter.
• Across five years, Capital Leases topped out at $32.2 million in Q2 2023 and bottomed at $16.6 million in Q1 2023.
• The 4-year median for Capital Leases is $31.1 million (2024), against an average of $30.0 million.
• Across the five-year window, Capital Leases jumped 91.41% in 2024 and slipped 3.28% in 2026, its largest moves.
• Year by year, Capital Leases stood at $31.9 million in 2023, then decreased by 2.48% to $31.1 million in 2024, then fell by 3.1% to $30.1 million in 2025, then dropped by 0.9% to $29.9 million in 2026.
• Per Business Quant, the three latest MRVI Capital Leases figures stand at $29.9 million (Q1 2026), $30.1 million (Q4 2025), and $30.4 million (Q3 2025).